Business Wire

NY-SNOWPLUS

4.6.2021 01:02:05 CEST | Business Wire | Press release

Share
Snowplus Experiences Global Growth Despite COVID

Snowplus , a leading global vape company, and its global business have flourished despite challenges posed by the COVID pandemic that has impacted business around the world. Their strategy of localization implemented in late 2019 has proven to be the key to their continual growth in the face of the pandemic. Since the pandemic started they have still seen a growth increase of around 350% in their global business.

Business impacts of the pandemic have been far reaching, including but not limited to logistics, manufacturing, and local economies being shut down. For the vape industry, it has been no different. However, localized strategies have enabled responsive and agile decision making, and have also minimized any negative impact from the current unforeseen global crisis.

Local Partners

In multiple new markets Snowplus has expanded to, they’ve been able to partner with leading companies that know their local markets well. To win the confidence of top level partners, a combination of quality products, reliable support, and long term investment have proven to be the key.

“Our focus on producing consistently high quality, rigorously tested products have helped us win major partnerships in markets we expand to,” explained Derek Li, Snowplus Cofounder and Head of Overseas Markets. “It’s always a satisfying moment when potential partners test our products, have a ‘wow’ moment, and come back to us ready to work something out.”

Local Strategies

In Canada, Snowplus realized quickly that finding a respected local e-liquid partner would bring down costs associated with e-liquid production and international shipping. But even more importantly, the Canadian palate was quite different from the flavors that make Snowplus pods a hit in Asia. Instead of hoping to have the market warm up to different taste profiles, tailoring flavors that fit local vapers has netted immediate market growth.

In fact, Canada is not the only market where Snowplus implements this two-pronged strategy of establishing local partners and executing local strategies. As a result, not only is Snowplus one of the fastest growing vape brands in the world according to device shipments since they started in 2019, they’ve achieved record growth during the pandemic.

“From our 28-point testing, the most thorough in the industry, to our high-tech laboratories in Shenzhen, our dogged dedication to product quality has opened doors for us in new markets and won over market leading partners wherever we go,” said Li. “In turn, it's been relatively easy for us to work with our local partners and trust their strategies, which has really carried us through this past year of difficulty. In the end, to still achieve record growth has been something we’re extremely proud of and grateful for. We’re not done. As the world slowly emerges from the pandemic, we’re open to any partners that are ready to work with us. Just reach out.”

ABOUT SNOWPLUS

Founded in April 2019, Snowplus is dedicated to replacing combustible tobacco through consistent quality and a commitment to innovating better vaping experiences. Snowplus products have passed a number of third-party safety certifications and are made with components that meet the highest medical safety standards. To date, Snowplus has received over $150 million in financing which is among the largest funding for any startup in the e-cigarette industry.

To learn more about Snowplus, please go to snowplustech.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye